What do systematic reviews say?

Paracetamol vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paracetamol vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paracetamol vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NSAIDs vs placebo

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.5, 1.38]
  13 studies · 1007 participants
  Moderate

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 1.05 [0.83, 1.32]
  9 studies · 801 participants
  Moderate

Summary of findings table ‐ Rifaximin vs placebo or no intervention

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 214 participants
  Moderate

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.56 [0.42, 0.77]
  13 studies · 1009 participants
  Moderate

Summary of findings table ‐ Rifaximin vs placebo or no intervention

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 2.79 [0.44, 17.78]
  6 studies · 639 participants
  Very low

Summary of findings table ‐ Rifaximin vs placebo or no intervention

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 381 participants
  Low

Summary of findings table ‐ Rifaximin vs placebo or no intervention

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 203 participants
  Moderate

Vitamin D vs placebo

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1188 participants
  Moderate

Vitamin D vs placebo

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1023 participants
  Very low

Vitamin D vs placebo

Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  RR 0.69 [0.44, 1.07]
  3 studies · 584 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 191 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 138 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 136 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 187 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 127 participants
  Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 123 participants
  Moderate